Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 10/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.89 |
| ▸ | THRB | P10828 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anabaseine SCHEMBL30394330 | 1.00 | CHRNB4 (1.00) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL6807730 | 0.98 | CHRNB4 (0.96) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL6807223 | 0.98 | CHRNB4 (0.96) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL6807728 | 0.98 | CHRNB4 (0.96) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| Myosmine SCHEMBL5319476 | 0.94 | ALDH1A1 (1.00) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| Myosmine SCHEMBL29398376 | 0.94 | ALDH1A1 (1.00) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL895500 | 0.78 | CHRNB4 (1.00) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL6797483 | 0.76 | CHRNB4 (0.96) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL3161806 | 0.76 | — | — | |
| SCHEMBL9481812 | 0.72 | CYP2A6 (0.58) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1126846-B1 | Use of a nicotine receptor agonist for the manufacture of a medicament for the treatment of obsessive compulsive disorder | CARLSSON A RESEARCH AB (SE) | 2003-08-06 | — | — | EP | claimed |
| US-20260126455-A1 | Methods and Dosing Regimens for Preventing or Delaying Onset of Alzheimer's Disease and Other Forms of Dementia and Mild Cognitive Impairment | ZACHRIEL NEUROSCIENCES LLC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12435353-B2 | Biomarker assay for use in monitoring autism | STALICLA SA (CH) | 2025-10-07 | — | — | US | disclosed |
| CN-118818043-A | Biomarker detection for monitoring autism | 斯塔利克拉股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240011071-A1 | BIOMARKER ASSAY FOR USE IN MONITORING AUTISM | STALICLA SA (CH) | 2024-01-11 | — | — | US | disclosed |
| CN-116113405-A | Pharmaceutical composition for preventing or treating viral infection | L·曼恩特托马斯 | 2023-05-12 | — | — | CN | disclosed |
| US-20220339166-A1 | POST COVID19 VACCINE REMEDIES | IPRX, LLC | 2022-10-27 | — | — | US | disclosed |
| US-20210251848-A1 | TREATMENT OF BLEEDING BY NON-INVASIVE STIMULATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-19 | — | — | US | disclosed |
| US-10912712-B2 | Treatment of bleeding by non-invasive stimulation | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190275020-A1 | METHODS AND COMPOSITIONS FOR INCREASING MUCUS CLEARANCE | THE UAB RESEARCH FOUNDATION | 2019-09-12 | — | — | US | disclosed |
| EP-0787724-A1 | NOVEL INTERMEDIATE FOR PRODUCTION AND PROCESS FOR PRODUCING PYRIDINE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
| US-5602257-A | Synthesis of nicotinic analogs | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 1997-02-11 | — | — | US | disclosed |
| US-5530134-A | Synthesis of anabaseine, salts and derivatives thereof | SYNPHAR LABORATORIES INC. (CA) | 1996-06-25 | — | — | US | disclosed |
| US-5516785-A | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0659078-A4 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM. | UNIV FLORIDA (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0659078-A1 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1995-06-28 | — | — | EP | disclosed |
| EP-0573568-A4 | USE OF NICOTINIC ANALOGS FOR TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIV FLORIDA (US) | 1994-09-21 | — | — | EP | disclosed |
| WO-1994005288-A1 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0573568-A1 | USE OF NICOTINIC ANALOGS FOR TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992015306-A1 | USE OF NICOTINIC ANALOGS FOR TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275020-A1 | METHODS AND COMPOSITIONS FOR INCREASING MUCUS CLEARANCE | CFTR, MUC1, SLC26A4 | CHRNB4 535/4885CHRNA3 902/4885ALDH1A1 1418/4885 |
| US-20260126455-A1 | Methods and Dosing Regimens for Preventing or Delaying Onset of Alzheimer's Disease and Other Forms of Dementia and Mild Cognitive Impairment | CHRNA7, CHRNA9, CHRNA6 | CHRNB4 18/4885CHRNA3 9/4885ALDH1A1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.